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ABSTRACT: 
The aim of the study was to prepare and statistically optimize transdermal formulation of antidiabetic drug Glimepiride (Glmp). In 
the present investigation Protransfersome gel (PTG) of glimepiride was prepared by modified coacervation phase separation 
technique and characterised for various parameters like vesicles shape, vesicles size and size distribution, entrapment efficiency 
and stability. Box-Benkhen model was chosen as optimization design. Three factors (amount of phospholipids, amount of 
surfactant and amount of drug) were varied at three levels Box-Benkhen statistical experimental design. These factors were found 
to have significant effects on the vesicular size (296.6±1.2nm), PDI(0.241±0.4) and drug loading(71.90±4.8%) and were optimized 
based on the desirability of the responses. The skin permeation studies were performed for 24 hours on pig ear skin using Franz 
diffusion cell. The flux value obtained from PTG (5.129±1.24 µg/cm2/h) was greater as compared to the drug suspension (0.430 
µg/cm2/h). PTG formulation showed good stability at 4±10C and after 3 months of storage there was no change in liquid crystalline 
nature, size of vesicles, drug content and other characteristic parameters observed. In vivo pharmacokinetic study of PTG showed 
significant drug release as compared to plain transdermal patch of the drug. Hence, present study reveals that PTG generates a new 
breakthrough for the transdermal delivery of Glimepiride with higher bioavailability, negligible gastrointestinal and hepatic side 
effects and increased patient compliance. 
Keywords: Glimepiride, protransfersome gel, optimization 
 
INTRODUCTION: 
Diabetes mellitus (DM) is a serious world health 
problem defined as group of metabolic disease 
characterised by hyperglycemia resulting from defects 
in insulin secretion or insulin activity or both. Type 2 
DM is associated with obesity and insulin resistance, 
together with defects in beta cell function
1
.
 
Glimepiride is a medium to long acting 3
rd
 generation 
sulphonylurea antidiabetic drug which is indicated to 
treat type 2 DM. It acts as an insulin secretagogue. It 
lowers blood sugar by stimulating release of insulin by 
pancreatic beta cells and by inducing increased activity 
of intracellular insulin receptor
2
. It is available in the 
form of tablet and suspension in the market with the 
dose of 2, 4, 8 mg per day.  
Direct delivery of antidiabetic drug glimepride using 
oral approach is not suitable because it produces 
hypoglycaemia during initial hours of oral 
administration and irregular bioavailability due to low 
solubility in water and poor patient compliance. It is 
also associated with gastrointestinal side effects and 
hepatic side effects (like cholestatic jaundice)
 3
. Thus, 
this necessity improved drug delivery via transfersome 
approach which enhanced delivery of this drug via the 
skin barrier, significantly improving bioavailability as 
well as patient compliance due to its ultradeformabilty 
property. The concept of ultradeformable or highly 
elastic vesicles was introduced in 1992 first by Gregor 
Cevc as new generation of vesicles, known as 
transfersomes, composed of phospholipids and 
surfactants called as edge activators
7,8
. The edge 
activator refers to the single chain surfactants which 
causes destabilization of the lipid bilayer. In addition, it 
also increases the vesicle-elasticity or fluidity. Later in 
1999, the second generation of the elastic vesicles were 
introduced by Van den Berg
7,8
. These vesicles consist of 
a micelle forming and a bilayer forming surfactant as 
destabilizing and stabilizing portion, respectively. In 
order to overcome the stability problem liquid 
crystalline pro-ultraflexible lipid vesicles 
“Protransfersome” were proposed, that will be 
converted into ultraflexible lipid vesicles transfersomes 
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also known as elastic liposomes, in situ by absorbing 
water from the skin
4,5
.  Protransfersomes provide higher 
stability and better skin penetration ability than the 
traditional lipid vesicles, e.g. liposomes, niosomes, etc
6
. 
The proposed Pro-T gel is a liquid crystalline gel in 
which the drug is intercalated within phospholipids
9
. 
MATERIALS AND METHODS 
Glimepiride was procured from Panacea Biotec, Delhi, 
India. L-α- phosphatidylcholine and sodium 
deoxycholate from Sigma Aldrich Co., St. Louis, 
U.S.A. Disodium hydrogen phosphate, Hydrochloric 
acid and sodium hydroxide were purchased from RFCL 
limited, New Delhi, India. All reagents used in this 
study were of analytical grade. 
Preparation of ProTransfersomal Gel 
Protransferosomal gel (ProT-gel) was prepared with 
slight modifications as reported by Perrett et al 
10
. Soya 
phosphatidylcholine, sodium deoxycholate, drug 
(Glmp) and alcohol were weighed and collected in an 
amber colored vial. All the components were then 
mixed with the help of a magnetic bead at a temperature 
of 60-70⁰C, while keeping the open end of the vial 
closed, in order to prevent the loss of solvent. Then 100 
mL phosphate buffer saline (pH 7.4) was added at the 
same temperature with continuous stirring, which lead 
to the formation of less viscous translucent liquid. This 
liquid composition was converted into the ProT-gel 
with overnight cooling at room temperature
10
. 
Preparation of Transfersomes from 
ProTransfersome  
ProT-gel (100 mg) was hydrated using 10 mL of 
phosphate buffer saline (pH 7.4) with manual shaking to 
produce transferosomal formulation for in-vitro 
evaluations.  
Optimization 
Response Surface Methodology – The Box-Behnken 
Model 
Optimization was carried out with response surface 
methodology (RSM) by the means of Box–Behnken 
model. Factors such as amount of soya 
phosphatidylcholine, amount of sodium deoxycholate, 
and amount of drug (Glmp) were found to be 
significantly affecting the encapsulation efficiency of 
the drug, and size of the carrier, estimated by a series of 
hit and trial formulations. Hence, these three factors 
were varied at 3 levels while keeping the other factors 
such as type of alcohol, amount of alcohol, amount of 
buffer, stirring speed, and stirring temperature constant. 
The independent variables X1, X2, X3 are listed in 
Table1. Based on the results of hit and trial 
formulations and literature study, appropriate ranges of 
the components were chosen as listed in table. Design 
Expert software was used to optimize the formulation 
and to develop the mathematical (quadratic) 
equations
11
. 
 
Table 1: Independent Variables and Their Levels in Box–Behnken design 
Independent Variables Level 
-1 +1 
X1 = Amount of soya phosphatidylcholine (SPC) (mg) 375 475 
 X2 = Amount of sodium deoxycholate(SDC) (mg) 25 125 
 X3 = Amount of drug (Glimepiride) (mg) 1.25 5.0 
                         Where, -1 signifies minimum amount and +1 signifies maximum amount 
 
Characterization  
Vesicle Size and Shape Analysis  
Size (Z-Average diameter) and the polydispersity index 
(PDI) of transfersomes derived from ProT-gel were 
analyzed by dynamic light scattering technique (DLS), 
using Zetasizer Nano ZS (Malvern Instruments Ltd., 
USA) at 25⁰C, and at an angle of 173⁰. The PDI relates 
with the width of vesicle size distribution and its small 
value (< 0.1) points towards homogeneity, while a high 
value (> 0.3) indicates high heterogeneity. All the 
measurements were conducted in triplicate
10
.Shape, 
size, and surface morphology of the transfersomes 
formed after hydration were confirmed by high 
resolution TEM at 300 kV (FEI, Technai G2 30 
UTWIN). Samples were obtained by dispersing the 
ProT-gel (hydrated transfersomes) (0.1 mL) into 15 mL 
of double distilled water (diluted up to 150 times). A 
drop of prepared dispersion was stratified over a 
carbon-coated copper grid for approximately 15 min. 
Excess dispersion was removed with a filter paper and 
the sample was subsequently dried in a desiccator for 60 
minutes. Sample was then loaded on the probe and 
observed under transmission electron microscope. 
Encapsulation Efficiency (%)  
Hydrated ProT-gel formulation (1mL) was centrifuged 
for 35 min at 12,000 rpm and 4˚C using an 
ultracentrifuge (Hettich, Germany). The supernatant 
was analysed to determine the unentrapped fraction of 
drug (Glmp) using UV spectrophotometer (Shimadzu, 
USA)
12
. 
The EE (%) was calculated by using the following: 
      
                          
                 
    . 
Drug Loading (%) 
The DL (%) was calculated by using the following: 
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    . 
Drug Release Study 
The kinetics of drug (Glimepiride) release from the 
ultradeformable transferosomal preparation formulated 
as ProT-gel was determined by modified diffusion cell 
using pig ear skin as a membrane. The values were put 
into various kinetic equations and respective graphs 
were plotted such as: Zero order release kinetics, first 
order release kinetics, and Higuchi model. Release 
profiles were further evaluated using Korsmeyer-Peppas 
equation
15
 to study the transport mechanism of the 
preparation.  
In vitro Skin Permeation Studies
 
The pig skin was carefully cleaned with distilled water 
and mounted on a Franz diffusion cell assembly (Orchid 
Scientific, India) with an available diffusion area of 
1.43 cm
2
. Fluid in diffusion cells was maintained at 
37±0.5⁰C under continuous stirring13. The stratum 
corneum of skin confronted the donor section, and the 
dermis confronted the receptor section and the 
apparatus was assembled. Equal amounts of drug 
(Glmp) loaded Pro-T-gel formulation (optimised result 
by Box Benkhen statistical design) as well as drug 
(Glmp) suspended in hydroxyl propyl methyl cellulose 
(HPMC) gel (as control) were applied to the donor cells 
facing the topical side of the skin. Isotonic phosphate 
buffered saline (PBS,  pH 7.4) having small amount of 
40% (v/v) PEG 400, was added to the receptor chamber 
to mimic the transdermal water gradient across the 
epithelial and stratum corneum faced upward to the 
donor compartment (sink condition). Aliquots (1.0mL) 
of receptor solution were withdrawn periodically for 48 
h and replaced with the same volume of pre-warmed 
receptor solution
14
. Samples were analysed by validated 
HPLC method at λmax (228 nm), and amount of drug 
permeated was calculated. Each preparation was studied 
in triplicate and the results represent the average value. 
All the measurements were conducted in triplicate. 
Stability Studies  
Optimized ProT-gel formulation was divided into 2 
groups and stored at 4 ± 1⁰C and room temperature, 
respectively for 3 months in screw capped amber 
colored glass bottles. Formulations were evaluated for 
drug crystals under digital microscope, drug content 
remaining, vesicle size and PDI after every 30 days. 
Stability studies of each formulation were carried out in 
triplicate.  
In vivo pharmacokinetic studies 
For in vivo studies, 6-8 weeks male albino wistar rats 
(245-265g) were used as experimental animals. Animals 
were kept in plastic cages in climatically controlled 
rooms and fed with standard rodent food pellet diet. The 
studies were carried out as per the guidelines of the 
Council for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Govt of India and 
in accordance with the protocol duly approved by 
Institutional Animal Ethical Committee of Delhi 
Institute of Pharmaceutical Science and Research, New 
Delhi, India (Approval No. IAEC/2015/05 Dated: 
20/11/2015). Hair on backside of male wistar rat was 
removed on previous day of experiment. Dose of Glmp 
was selected by conducting hypoglycemic studies with 
dose of 1-10 mg/kg
16
. Following an overnight fast, rats 
were divided in to 3 groups (n=3) and were treated as 
follows: 
GroupI(Control): Patch containing Gel without drug 
GroupII: Patch containing Gel loaded with micronised 
drug 
GroupIII: Patch containing drug in Protransferomal Gel 
After the administration, blood samples (0.2mL) for 
pharmacokinetic analysis was collected from lateral tail 
vein in heparin tubes at time intervals between 1-48 hrs 
after treatment. Plasma was separated by centrifugation 
and then stored at -20ºC until assayed.Plasma samples 
were subjected to HPLC analysis, using Shimadzu 
UFLC system. Glimepiride concentration was 
calculated from linear regression calibration curves of 
peak height with respect to different plasma samples 
obtained after centrifugation. 
Statistical Analysis 
Data analysis was implemented with the software, 
GraphPad Prism (5.0). The data were reported as mean 
± S.D. (n = 3 or 6) and multiple comparisons of means 
(one way ANOVA, Dunnettpost test). Student’s t-test 
was performed for comparing two samples. Results 
were said to be significant at ≥ 95% confidence interval, 
p< 0.05 and are shown as the mean ± SD. 
 
RESULT AND DISCUSSION 
Optimisation  
Optimisation of Glmp loaded PTG was done by using 
Response Surface Methodology (RSM) : The Box-
Behnken Model. RSM is a collection of statistical and 
mathematical techniques useful for developing, 
improving, and optimizing processes in which a 
response of interest is influenced by several variables 
and the objective is to optimize this response. RSM, 
which includes factorial design and regression analysis, 
helps in evaluating the important factors, building 
models to study the interactions between the variables, 
and selecting the optimum conditions of variables or 
desirable responses
11
. Box–Behnken statistical design 
was used to statistically optimize the significant 
formulation factors and evaluate their quadratic effects 
on size, PDI, zeta potential, and drug loading. The 
values of remaining parameters were kept constant 
throughout the Box-Behnken method. A design matrix 
comprising of 17 experimental runs with 5 centre points 
was constructed by varying 3 factors over 3 levels. The 
possible 17 combinations generated by the Design 
Expert (Version 9, Stat-Ease Inc., Minneapolis, MN) 
were run and responses were recorded. The independent 
variables and the responses for all 17 experimental runs 
are given in Table 2.  
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Table 2: Box Behnken Experimental Design with Measured Responses 
Run X1 X2 X3   Size (nm)       PDI Drug Loading (%) 
1 425 75 3.125 279.11 0.353 70.20 
2 425 125 5 499.21 0.331 68.38 
3 375 25 3.125 721.31 0.584 52 
4 475 25 3.125 819.75 0.666 54.9 
5 375 75 5.00 292.01 0.279 66 
6 475 75 5.00 394.45 0.343 61.9 
7 425 75 3.125 287.32 0.35 71.21 
8 425 125 1.25 380.69 0.302 45 
9 425 75 3.125 288 0.351 72.41 
10 425 75 3.125 287.26 0.353 70.02 
11 375 75 1.25 265.66 0.266 39.12 
12 375 125 3.125 545.25 0.281 64.5 
13 475 75 1.25 332.25 0.323 41.87 
14 425 75 3.125 286.92 0.355 71.11 
15 425 25 1.25 642 0.633 36.62 
16 425 25 5.00 685 0.642 61 
17 475 125 3.125 619 0.309 57 
X1: amount of soya lecithin, X2: amount of SDC, X3: amount of drug 
 
The dependent variables i.e. Size, PDI and drug loading 
obtained at various levels of 3 independent variables 
(X1, X2, X3) were subjected to multiple regression to 
yield second order polynomial equation. A positive 
value represents an effect that favours a better value of 
a given response, while a negative value indicates an 
antagonistic relationship between the factor and the 
response. The following regression equations were 
given by the design: 
Regression Equations 
Size = + 5972.08299 - 22.42457X1 - 19.79207X2 + 
39.67556X3 - 3.00800E - 003X1X2 + 0.098107X1X3 + 
0.027787X2X3 + 0.030638(X1)
2
 + 0.12768(X2)
2
 - 
12.18500(X3)
2 
 
This indicates that amount of soya lecithin and SDC has 
unfavourable effect while amount of drug has 
significant favourable effect on size. The positive 
coefficient for interaction between 2 variables (X1X3, 
X2X3) indicates favourable effect on size if combined 
together. 
PDI = -1.93453 + 0.012255X1- 9.68217E - 003X2 + 
0.02182X3 - 5.40000E - 006X1X2 + 1.86667E – 
005X1X3 + 5.33333E - 005X2X3 - 1.33300E - 005(X1)
2 
+ 5.63700E - 005(X2)
2
 - 4.64356E - 003(X3)
2
 
Amount of SDC has unfavourable effect while amount 
of drug and soya lecithin has favourable effect on PDI. 
The negative coefficient for interaction between 2 
variables (X1X2, X1X3, X2X3) indicates unfavourable 
effect on PDI if combined together. 
Drug loading (%)= -599.30903 + 2.71778X1+ 
1.00024X2 + 37.40711X3 - 1.10000E - 003X1X2 - 
0.021333X1X3 - 2.98483E - 017X2X3 - 3.03660E - 
003(X1)
2 
- 3.03460E - 003(X2)
2 
- 3.51047(X3)
2
 
The above equation for drug loading indicates that the 
amount of soya lecithin, SDC, and drug, positively 
increase drug loading (%) in the ProT-gel.  
From the above result the final optimised formulation 
was prepared which gave the result as given in Table 3.
 
                 Table 3: Box-Behnken design results for optimized Glimepiride loaded ProT-gel 
Amount of SPC 
(mg) 
Amount of SDC 
(mg) 
Amount of Drug 
(mg) 
Size PDI Drug 
Loading 
Desirability 
406.266 92.494 2.122 296.848 0.300 72.4 0.954 
 
 
Size, PDI and Entrapment Efficiency 
To determine the vesicles shape Transmission Electron 
Microscopy (TEM) study was carried out (Figure1). 
Vesicles size and size distribution was determine by 
optical microscope. The size was found to be 296 nm 
with the PDI of 0.25 and the maximum entrapment 
efficiency of vesicles was found to be 68%. 
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Figure 1: Photomicrograph [TEM at 300 kV] of 
transfersomes reconstituted from ProT-gel formulation. 
In vitro Skin permeation studies  
In vitro skin permeation studies were carried out on the 
optimized formulation and were compared with the 
drug suspension. Significant augmentation in the skin 
permeation of the drug has been observed (Figure 2) 
with vesicular formulation as the percent cumulative 
drug permeated through the skin was 9.00±2.2 % for 
drug suspensions whereas the amount of drug 
permeated through the ProT-gel formulation was 
82.50±9.8%. ProT-gel system provides a greater flux 
(5.129±1.24 µg/cm
2
/h) as compared to the drug 
suspension (0.430 µg/cm
2
/h) for Glimepiride (Figure 
2). Reduction in lag time for Glimepiride was observed 
with the ProT-gel system. After spontaneous 
transformation of ProT-gel into transferosomal vesicles 
(due to water permeation from the receptor 
compartment to the skin under non-occlusive 
conditions) two mechanism, (a) penetration enhancing 
effect and (b) the intact vesicular permeation through 
the skin, might simultaneously prevail the permeation 
of drug depending upon the vesicular composition, 
characteristics, and physicochemical properties of 
entrapped drug. Other reasons for enhanced permeation 
profile from ProT-gel carriers could be (a) better EE% 
of drug in transfersomes, (b) completely encapsulated 
drug within the vesicles, (c) alcohol providing 
penetration enhancement, and (d) membrane elasticity 
of the developed vesicular system. Due to spontaneous 
transformation of ProT-Gel into transferosomal 
vesicles, rapid drug permeation was detected for 
Glimepiride initially. Suspension demonstrated 
minimal to negligible permeation of drug over a period 
of 48 h. However, a sustained effect was observed with 
the ProT-gel formulation.  
 
 
Figure 2: Cumulative drug release (%) from optimized ProT-gel formulation and micronized drug patch, through the 
ear skin of pig (Data are mean ± SD; n = 3) 
 
Table 4: Permeation rate (µg/cm
2/
h) at steady state along with the permeation enhancement ratio (Er) 
Formulation Drug flux (permeation rate) at steady 
state (µg/cm
2
/h) 
Enhancement ratio 
(Er) 
Glmp loaded Protransfersome gel  5.129 11.927 
Gel containing micronized Glmp 0.430 - 
 
Release study 
The release from ProT-gel formulations was subjected 
to different model dependent kinetics (zero order, first 
order, Higuchi model release kinetics and Korsmeyer-
Peppas model, Fig.4 (a), (b), (c) and (d) respectively). 
The release profile exhibiting maximum R
2 
value was 
found to obey Higuchi model release kinetics for ProT-
gel formulations (Table 4). Hence, ProT-gel 
formulations follow Higuchi model drug release 
mechanism which means formulation exhibits an initial 
burst release followed by sustained drug release.  
Korsmeyer-Peppas kinetics model was also analysed to 
see whether it was following Fickian diffusion (n= 0.5), 
anomalous transport (0.5< n<1.0), case-II transport (n= 
1), or super case-II transport (n>1). A graph was plotted 
between the percentage cumulative release and log time 
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(h). Release exponent (n), and correlation coefficient 
was analysed (Fig. 4 d). The release exponent (n) for 
the optimised ProT-gel formulation was found to be 
0.8588. Therefore, the formulation followed Higuchi 
and anomalous transport for drug release.  
              
Table 5: Release rate constants (k), correlation coefficients (R
2
), and release exponent (n) of optimized ProT-gel 
formulation 
Zero order First order Higuchi Korsemeyer-Peppas 
n R
2
 n R
2
 n R
2
 n R
2
 
7.67±0.812 0.599 0.277±0.058 0.695 18.69±0.101 0.9700 0.8588 0.897 
 
Stability Studies 
The storage stability of the colloidal carriers is the 
foremost restriction in the preparation of clinically 
appropriate marketed formulations.  The influence of 
aging on EE% was not too significant in the case of 
refrigerated temperature (Table 5). Reason for increased 
consistency of ProT-gel might be due to a possible 
molecular interaction of surfactant’s polar head groups 
with the solvent and permeation of solvent into bilayer. 
Vesicle size increased whereas PDI decreased 
indicating complete swelling of bilayer as the solvent 
diffused into the bilayers completely with time and 
hence more uniform vesicles were formed upon storage.  
 
Table 6: Effect of storage on vesicle size, PDI, and Encapsulation Efficiency 
           Time (months) Temp. (4±1ºC) Temp (Ambient Conditions) 
 
 
Vesicle size (nm) 
0 day 310.5±1.2 
1  394.2±1.2 340.1±2.3 
2  408.6±0.8 550.9±0.3 
3 s 520.6±1.1 610.8±0.9 
 
Poly Dispersibilty Index 
(PDI) 
0 day 0.258±0.4 
1  0.230±0.6 0.394±3.1 
2  0.242±1.9 0.326±0.7 
3  0.241±0.5 0.298±0.4 
 
Encapsulation Efficiency 
(%) of Glmp 
0 day 68.180±8.3 
1  66.421±9.1 58.960±4.6 
2  
3  
65.910±4.0 
64.011±6.8 
46.224±1.6 
43.190±7.3 
 
In vivo kinetic studies: 
 
Figure 3: Comparison in drug release from micronised 
drug patch and protansfersomal gel formulation 
In vivo studies in male wistar rats revealed that very 
low concentration of drug in plasma was achieved 
when micronized drug in gel was applied whereas 
when optimised Glmp loaded pro-transfersome patch 
was applied, it showed extensive increase in the drug 
release which was maintained over 48 hours (Figure 
3). These results established the sustained and 
prolonged delivery of Glimepiride from pro-T gel 
formulation and ability to maintain constant drug 
concentration over 48 hours. Based on in vivo results, 
it can be concluded that investigated carrier system 
provided accentuated delivery through alongwith 
controlled and prolonged delivery of Glimepiride. 
CONCLUSIONS 
Results of present study established that introduction 
of ProT-gel generates a new breakthrough for the 
transdermal delivery of Glimepiride and exhibited 
improved release kinetics. It anticipate numerous 
advantages for instance bypassing first pass 
metabolism, counting a higher bioavailability, 
negligible gastrointestinal side effect, less long term 
effects due to smaller amounts of drug administered, 
and most importantly increased patient compliance 
(with availability of patch system) which is foremost 
in treatment of such a life-time disorder. 
0 
200 
400 
600 
800 
1000 
1200 
1400 
0 20 40 60 
cu
m
u
la
ti
ve
 d
ru
g 
re
le
as
e
(m
g)
 
Time (hours) 
In vivo kinetic study 
Glmp Pro transfersome Gel 
Micronised Glmp transdermal patch 
Chauhan et al                                     Journal of Drug Delivery & Therapeutics. 2016; 6(4):48-54                                54 
© 2011-16, JDDT. All Rights Reserved                                   ISSN: 2250-1177                                  CODEN (USA): JDDTAO 
 REFERENCES 
1. Kitabchi AE, Umpierrez, GE, Miles JM and Fisher JN, 
Hyperglycemic crises in adult patients with diabetes,  
Diabetes Care 32, 2009, 7, 1335–43. 
2. Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycemia: report of a WHO/IDF 
consultation (PDF), Geneva: World Health Organization. 
2006, 21. 
3. Ripsin CM, Kang H and Urban RJ, Management of blood 
glucose in type 2 diabetes mellitus, Am Fam Physician, 
2009, 79, 29–36. 
4. Cevc G, Blume G, Schatzlein A, Gebauer D and Paul A, The 
skin: a pathway for systemic treatment with patches and 
lipid-based agent carriers, Advanced Drug Delivery Reviews, 
1996, 18, 349-378. 
5. Helfrich W, Elastic Properties of Lipid Bilayers: Theory and 
Possible Experiments, Nature Sch., 1973, 28, 693-703. 
6. Cevc G, Transfersomes, Liposomes and Other Lipid 
Suspensions on the Skin: Permeation Enhancement, Vesicle 
Penetration, and Transdermal Drug Delivery, Critical 
Reviews in Therapeutic Drug Carrier Systems, 1996, 13(3-
4), 257-388.  
7. Cevc G and Blume G, Lipid vesicles penetrate into intact 
skin owing to the transdermal osmotic gradients and 
hydration force, Biochimica et Biophysica Acta (BBA) – 
Biomembranes, 1992, 1104, 226-232. 
8. Loan Honeywell-Nguyen P , Wouter Groenink H and 
Bouwstra J, Elastic Vesicles as a Tool for Dermal and 
Transdermal Delivery, Journal of Liposome Research, 2006, 
16, 273-280.  
9. Cevc G, Material Transport Across Permeability Barriers by 
Means of Lipid Vesicles.Structure and Dynamics of 
Membranes - From Cells to Vesicles, 1995, 465-490.  
10. Perrett S, Golding M and Williams W. A, Simple Method for 
the Preparation of Liposomes for Pharmaceutical 
Applications: Characterization of the Liposomes, Journal of 
Pharmacy and Pharmacology, 1991, 43, 154-161. 
11. Elsayed M, Abdallah O, Naggar V and Khalafallah N, 
Deformable liposomes and ethosomes: Mechanism of 
enhanced skin delivery, International Journal of 
Pharmaceutics, 2006, 322, 60-66. 
12. Malakar J, Sen S, Nayak A and Sen K, Formulation, 
optimization and evaluation of transferosomal gel for 
transdermal insulin delivery, Saudi Pharmaceutical Journal, 
2012, 20, 355-363. 
13. Verma N, Verma A and Dubey J, Formulation and 
Evaluation of chitosan containing mucoadhesive buccal 
patches of metoprolol succinate, Journal of drug delivery and 
therapeutics, 2016, 6, 14-20. 
14. Chaudhary H, Kohli K and Kumar V, Nano-transfersomes as 
a novel carrier for transdermal delivery, International Journal 
of Pharmaceutics, 2013, 454, 367-380. 
15. Verma N, Verma A and Dubey J, Formulation and 
Evaluation of chitosan containing mucoadhesive buccal 
patches of metoprolol succinate, Journal of drug delivery and 
therapeutics, 2016, 6(2), 14-20. 
16. Srinivas M, Nayanabhirama U, Sharath K, Sunil A, Ganesh S 
and Averineni K.R, Glipizide matrix transdermal system for 
diabetes mellitus: preparation, in vitro and preclinical 
studies, 2006, 79, 1568-1577. 
 
 
How to cite this article: 
Chauhan MK, Gulati A, Aggrandized transdermal delivery of glimepiride via transfersomes: formulation, 
evaluation and statistical optimization, Journal of Drug Delivery & Therapeutics. 2016; 6(4):48-54 
 
